In addition, administering the CXCR4 antagonist AMD3100 to mice prior to the nanoconjugate completely blocked its tumor uptake (Fig 2D) as well as its internalization in CXCR4+ cancer cells (Fig 2E and F). This evidence concerns the gene CXCR4 and neoplasm.